TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Dimerix Limited ( (AU:DXB) ) has issued an announcement.
Dimerix Limited has announced the application for quotation of 41,710 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of an employee incentive scheme, indicating a strategic effort to motivate and retain talent within the company, which could positively impact its operational capabilities and market positioning.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited is a company operating in the biotechnology industry, focusing on the development of innovative therapies. The company is primarily engaged in creating treatments for unmet medical needs, with a market focus on rare and chronic diseases.
Average Trading Volume: 2,006,601
Technical Sentiment Signal: Buy
Current Market Cap: A$312.1M
See more insights into DXB stock on TipRanks’ Stock Analysis page.